Impacts of colistin sulfate on fecal Escherichia coli resistance and on growth performance of piglets in a post-weaning diarrhea model

Mohamed Rhouma1,2,3, Francis Beaudry4, William Thériault1,2,3, Nadia Bergeron1,2,3, Sylvette Laurent-Lewandowski1,2,3, John Morris Fairbrother2,3,5, Ann Letellier1,2,3,4*

1Chaire de recherche en salubrité des viandes (CRSV), 2Groupe de recherche et d'enseignement en salubrité alimentaire (GRESA), 3Centre de recherche en infectiologie porcine et avicole (CRIPA), 4Groupe de recherche en pharmacologie animale du Québec (GREPAQ), 5OIE Reference Laboratory for Escherichia coli (EcL). Faculté de médecine vétérinaire – Université de Montréal

*e-mail: ann.letellier@umontreal.ca

Abstract

Colistin sulfate (CS) is used in Canada for the treatment of post weaning diarrhea (PWD), to overcome conventional therapeutic antibiotics failures. The aim of the present study was to determine the effect of a conventional oral regimen of CS for the treatment of PWD, on the development of E. coli CS resistance and to evaluate the effect of ETEC: F4 infection on CS intestinal absorption.

A total of 48 pigs were used, challenge was carried out by oral administration of 10⁹ CFU of a hemolytic ETEC: F4 strain resistant to nalidixic acid. CS was administered at a dose of 50,000 UI/kg twice a day for 5 days. Feces were examined clinically and bacteriologically before and after challenge to evaluate presence of diarrhea and E. coli fecal excretion. ETEC: F4 virulence factors were monitored and CS plasma concentrations were quantified by an HPLC-MS/MS.

From one until six days after CS administration, a significant reduction in the fecal excretion of ETEC: F4, total E. coli, ETEC: F4 virulence factors and in diarrhea scores was observed in the challenged treated group compared to the challenged untreated group (p<0.0001). No significant difference in growth performances was observed in treated compared to non-treated pigs (p>0.71). A significant selection pressure on E. coli total population was observed following CS treatment (p<0.0001). Challenge with ETEC: F4 resulted in an increase in intestinal absorption of CS in the challenged group compared to the non-challenged one.

Our study is the first to demonstrate in an experimental model of PWD, that CS at a dose of 50,000 IU/kg is effective in reducing fecal excretion of E. coli. However, this regimen was associated with a selection pressure on E. coli CS resistance, and did not improve growth performance in challenged pigs. Thus, the use of this antibiotic in pig should be revised.